Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019693 (
HIV
)
170,526
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Strategies that prevent initial
HIV infection
of cells are greatly needed. In this study, we determined the requirement of divalent cations for
HIV infection
of and attachment to peripheral blood mononuclear cells (PBMC), which contain several types of
HIV
-infectable cells-CD4(+) T cells, monocytes and dendritic cells.
EDTA
, added only during PBMC exposure to
HIV
, reduced infection by an average of 92%. The reduction of infection by
EDTA
was accompanied by a reduction in
HIV
binding to PBMC; R5, X4 and dual-tropic
HIV
binding to PBMC were inhibited by >85%. EGTA similarly reduced
HIV
binding to PBMC, while addition of Ca(2+) or Mn(2+), but not Mg(2+), fully restored binding. Virus attachment was inhibited in a dose-dependent manner by trypsin treatment of PBMC, indicating protein involvement in
HIV
binding. In contrast, mannan or soluble ICAM-1 did not inhibit
HIV
binding to PBMC. These data indicate that a Ca(2+)-dependent cell-surface protein(s) is responsible for the majority of
HIV
attachment to and infection of PBMC. Further studies of this are likely to reveal novel strategies to prevent infection of PBMC.
...
PMID:HIV infection of mononuclear cells is calcium-dependent. 1684 79
Serial measurements of absolute CD4+ T-lymphocyte counts are required to initiate and gauge response to therapy and monitor disease progression. Hence, there is an urgent need to evaluate the accuracy and validity of low-cost CD4+ T-cell count assays. Tripotassium
EDTA
blood specimens from
HIV
-infected individuals were studied using a novel flow cytometric assay (EasyCD4 assay; Guava Technologies, Hayward, CA) in comparison with standard flow cytometry (FACSCount; Becton Dickinson Immunocytometry Systems, San Jose, CA). The sensitivity, specificity value by EasyCD4 assay in enumerating absolute CD4+ T-cell counts of less than 200 cells/microL were 95% and 100%, respectively. Bland-Altman analysis showed close agreement, with the EasyCD4 assay yielding CD4+ T-cell counts a mean difference of -26 cells/microL (95% confidence interval, -96 to 44 cells/microL) higher than by flow cytometry. Our data suggest that EasyCD4 assay could be a useful alternative assay to conventional flow cytometry, may be appropriate for use in resource-limited settings.
...
PMID:A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings. 1688 80
Virion infectivity factor (Vif) is an accessory protein encoded by
HIV
-1 and is critical for viral infection of the host CD4(+) T cell population. Vif induces ubiquitination and subsequent degradation of Apo3G, a cytosolic cytidine deaminase that otherwise targets the retroviral genome. Interaction of Vif with the cellular Cullin5-based E3 ubiquitin ligase requires a conserved BC box and upstream residues that are part of the conserved H-(Xaa)(5)-C-(Xaa)(17-18)-C-(Xaa)(3-5)-H (HCCH) motif. The HCCH motif is involved in stabilizing the Vif-Cullin 5 interaction, but the exact role of the conserved His and Cys residues remains elusive. In this report, we find that full-length
HIV
-1 Vif, as well as a HCCH peptide, is capable of binding to zinc with high specificity. Zinc binding induces a conformational change that leads to the formation of large protein aggregates.
EDTA
reversed aggregation and regenerated the apoprotein conformation. Cysteine modification studies with the HCCH peptide suggest that C114 is critical for stabilizing the fold of the apopeptide, and that C133 is located in a solvent-exposed region with no definite secondary structure. Selective alkylation of C133 reduced metal-binding specificity of the HCCH peptide, allowing cobalt to bind with rates comparable to that with zinc. This study demonstrates that the HCCH motif of
HIV
-1 Vif is a unique metal-binding domain capable of mediating protein-protein interactions in the presence of zinc and adds to a growing list of examples in which metal ion binding induces protein misfolding and/or aggregation.
...
PMID:Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. 1713 31
Absolute values of the lymphocyte subsets are known to be influenced by various biological factors. We set out to determine if diurnal variations in lymphocyte subsets occur in our population. A prospective study was done on 25 randomly chosen healthy subjects. Persons were enrolled for the early morning to mid afternoon study i.e. 8:30, 12:30 and 15:30. In a second study, samples were collected at hourly intervals from 08:30 to 12:30. The
EDTA
samples were analyzed for lymphocyte subsets by flowcytomery. In the first study, the results have shown that there was a progressive increase in CD4 cell count throughout the day, while CD8 and CD19 cell counts increased between 08:30am and mid-day and then there was no further change between midday and mid afternoon. CD56 was uniform throughout the whole day. As most clinics and venesections take place in the morning, the aim of the second part of the study was to focus on the nature of the changes observed in the morning to midday phase. The results have shown that there were no significant changes in the lymphocyte subset counts before 11:30, thereafter there was a progressive increase in all of the lymphocyte subsets between 11:30 and 12:30 except for the CD56 cell count. This study has shown that diurnal rhythms influence the lymphocyte subsets in a normal population. This may have major implications in the use of CD4 subset analysis in the management of
HIV
infected persons as an indicator for initiation of treatment. In our setting. pending the results of diurnal variation studies on PLWHA, we have set the latest blood collection time at 11:30 am.
...
PMID:Analysis of diurnal variation of lymphocyte subsets in healthy subjects in the Caribbean, and its implication in HIV monitoring and treatment. 1720 28
An HPLC-MS/MS method was developed for the determination of MK-0518 (raltegravir), an
HIV
integrase inhibitor, in human plasma over the concentration range of 2-1000 ng/mL. Stable isotope labeled (13)C(6)-MK-0518 was used as an internal standard. The sample preparation procedure utilized liquid-liquid extraction with hexane:methylene chloride in the 96-well format with a 200 microL plasma sample size. The compounds were chromatographed on an Ace C(18) (50 x 3.0 mm, 3 microm, titanium frits) column with 42.5/57.5 (v/v %) 0.1mM
EDTA
in 0.1% formic acid/methanol mobile phase at a flow rate of 0.5 mL/min. Multiple reaction monitoring of the precursor-to-product ion pairs for MK-0518 (m/z 445-->109) and (13)C(6)-MK-0518 (m/z 451-->367) on an Applied Biosystem API 4000 HPLC-MS/MS was used for quantitation. Intraday precision of standard curve concentrations in five different lots of control plasma was within 3.2%, while accuracy ranged from 94.8 to 106.8%. The mean extraction recovery of spiked plasma samples was 87%. Quality control (QC) samples were stored at -20 degrees C. Initial within day analysis showed QC accuracy within 7.5% of nominal with precision of 3.1% or less. The plasma QC samples were demonstrated to be stable for up to 23 months at -20 degrees C. The method described has been used to support over 18 clinical studies during Phase I through III of clinical development.
...
PMID:Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. 1764 53
The identification of surfactant protein A (SP-A) as an important innate immune factor of the lungs, amniotic fluid, and the vaginal tract suggests that it could play an important role during various stages of HIV disease progression and transmission. Therefore, we examined whether SP-A could bind to
HIV
and also had any effect on viral infectivity. Our data demonstrate that SP-A binds to
HIV
in a calcium-dependent manner that is inhibitable by mannose and
EDTA
. Affinity capture of the
HIV
viral lysate reveals that SP-A targets the envelope glycoprotein of
HIV
(gp120), which was confirmed by ELISA using recombinant gp120. Digestion of gp120 with endoglycosidase H abrogates the binding of SP-A, indicating that the high mannose structures on gp120 are the target of the collectin. Infectivity studies reveal that SP-A inhibits the infection of CD4+ T cells by two strains of
HIV
(BaL, IIIB) by >80%. Competition assays with CD4 and mAbs F105 and b12 suggest that SP-A inhibits infectivity by occlusion of the CD4-binding site. Studies with dendritic cells (DCs) demonstrate that SP-A enhances the binding of gp120 to DCs, the uptake of viral particles, and the transfer of virus from DCs to CD4+ T cells by >5-fold at a pH representative of the vaginal tract. Collectively, these results suggest that SP-A acts as a dual modulator of
HIV infection
by protecting CD4+ T cells from direct infection but enhancing the transfer of infection to CD4+ T cells mediated by DCs.
...
PMID:Surfactant protein A binds to HIV and inhibits direct infection of CD4+ cells, but enhances dendritic cell-mediated viral transfer. 1856 27
The new Cobas AmpliPrep/Cobas TaqMan
HIV
-1 Qual test offers advanced automation for the detection of human immunodeficiency virus type 1 (HIV-1) RNA and DNA in dried blood spots (DBS) and whole blood. An analytical evaluation using an
HIV
-1 secondary standard yielded limits of detection of 514, 710, and 1,090
HIV
RNA copies/ml for
EDTA
plasma, whole blood, and DBS, respectively. The precision and reproducibility of
HIV
-1 detection was equivalent for DBS and whole blood. Inclusivity was demonstrated for a reference panel of
HIV
-1 subtypes A to N. A clinical evaluation of the Cobas AmpliPrep/Cobas TaqMan
HIV
-1 Qual test was performed at a center for routine diagnostics in Johannesburg, South Africa, using 1,013 clinical specimens from
HIV
-1 exposed children. The Amplicor
HIV
-1 DNA test v1.5 with the MagNApure DNA isolation procedure was used as the reference method. A total of 995 valid results for whole blood with both methods yielded 691 and 303 concordant negative and positive results for the Cobas AmpliPrep/Cobas TaqMan
HIV
-1 Qual test, respectively. For the 800 valid DBS specimen results, 495 and 300 concordant negative and positive results were obtained, respectively. The resulting clinical specificities and sensitivities of the new test were 100% and 99.7% for whole blood and DBS, respectively. The new test was characterized by its robustness, enhanced automation, and improved sample throughput. The Cobas AmpliPrep/Cobas TaqMan
HIV
-1 Qual test will support early, reliable diagnosis of
HIV
in children in routine laboratory settings.
...
PMID:Performance of a novel human immunodeficiency virus (HIV) type 1 total nucleic acid-based real-time PCR assay using whole blood and dried blood spots for diagnosis of HIV in infants. 1892 17
A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml
EDTA
-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log(10) copies/ml for the Versant, Amplicor, and NucliSens QT
HIV
-1 load assays, respectively (P, not significant). However, mean
HIV
-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log(10) copies/ml, depending on assay type (P < 0.05). Infectious
HIV
-1 was not recovered from dried ST plasma. There was no significant difference in
HIV
-1 viral load results obtained using ST after 8 weeks of storage at ambient temperature. Compared to frozen plasma,
HIV
-1 genotypic results were >99% concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including
HIV
-1 viral load,
HIV
-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.
...
PMID:Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. 1932 32
The human immunodeficiency virus type 1 (HIV-1) load is an important marker of disease progression and treatment efficacy in patients with
HIV
-1 infection. In recent years, an increase in the number of samples with detectable
HIV
-1 RNA has been reported among patients with previously suppressed viral loads, affecting clinical patient care and leading to repeat measurements of viral load and drug resistance. This rise seems to have coincided with the increased use of plasma preparation tubes (PPTs) for sample collection, and we have aimed to explain why PPTs might yield elevated
HIV
-1 RNA levels. The impacts of different sample-processing procedures on
HIV
-1 RNA levels were compared retrospectively. Prospectively, the presence of different cells and cell-associated
HIV
-1 nucleic acids in paired plasma samples from PPTs centrifuged before (PPT1) and after (PPT2) transportation to the laboratory was compared. A retrospective analysis of 4,049 patient samples with <1,000
HIV
-1 RNA copies/ml showed elevated
HIV
-1 RNA levels in plasma from PPT1 compared with the levels from PPT2 and standard
EDTA
-containing tubes. Prospective data revealed cell-associated
HIV
-1 nucleic acids and abundant blood cells in plasma from PPT1 but not from the corresponding PPT2. The levels of
HIV
-1 RNA correlated with the lymphocyte counts in plasma in PPT1. Cells could be removed by the recentrifugation of PPT1 before analysis. In conclusion, the transportation of PPTs after centrifugation may render cells in the plasma fraction containing cell-associated
HIV
-1 nucleic acids that contribute significantly to the
HIV
-1 RNA copy numbers in patients with low viral loads.
...
PMID:Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. 1942 Jan 66
An LC/MS/MS assay we published for tenofovir (TFV) plasma levels is a useful tool for monitoring the pharmacotherapy of
HIV
-positive individuals [T. Delahunty, L. Bushman, C.V. Fletcher, J. Chromatogr. B 830 (2006) 6-12]. A new combination therapy consisting of the TFV pro-drug (300 mg) and another reverse transcriptase inhibitor, emtricitabine (FTC, 200 mg) has become available in a convenient once-daily dosage form (Truvada). This widely used medication has prompted us to develop and validate a convenient assay to determine simultaneously TFV and FTC plasma concentrations. In view of their chemical similarity to the analytes, stable isotope internal standards (IS) were chosen. These consisted of TFV labeled uniformly with (13)C in the adenine moiety (Iso-TFV) and FTC labeled with 13C and 15N in the cytosine moiety (Iso-FTC). Trifluoroacetic acid was added to the patient's
EDTA
plasma (containing the IS) to produce a de-proteinated extract after high speed centrifugation. The extracts were directly injected into the mobile phase (3% acetonitrile/1% acetic acid, aq.) stream flowing at 200 microL/min. A Synergi Polar-RP, 2.0 mm x 150 mm, reversed-phase analytical column was used to achieve the chromatographic separation. Detection of the analytes was achieved by ESI positive ionization tandem mass spectrometry. The precursor/product transitions (m/z) in the positive ion mode were 288/176 and 293/181 ions for TFV and Iso-TFV, respectively and the precursor/product transitions (m/z) were 248/130 and 251/133 ions for FTC and Iso-FTC, respectively. When the analyte/IS abundance ratios were plotted against the specified concentrations, the linearity of the concentration curves were in the range 10 ng/mL to 1500 ng/mL for both analytes (250 microL plasma extracted), with a minimum quantifiable limit of 10 ng/mL for both analytes. The inter- and intra-day accuracy and precision for both TFV and FTC were within +/-20% at the LLOQ and +/-15% at the other QC levels. We have expanded the method originally designed for the assay of TFV alone to incorporate the simultaneous determination of the latter and FTC using stable isotope IS. This assay has been successfully used for the periodic monitoring of 678
HIV
-positive patients being treated with the combination therapy.
...
PMID:The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. 1949 10
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>